[
  {
    "ts": null,
    "headline": "Quantum Computing Stocks: Honeywell's Quantinuum Plans IPO",
    "summary": "Honeywell said its‌ quantum computing unit Quantinuum will filing for an IPO, adding to the growing number of quantum computing stocks.",
    "url": "https://finnhub.io/api/news?id=cd873ef285dd87cb3e5f766ef90832f29b6ad2267cb53c25e3f742b7a805e332",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768398080,
      "headline": "Quantum Computing Stocks: Honeywell's Quantinuum Plans IPO",
      "id": 138110996,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Honeywell said its‌ quantum computing unit Quantinuum will filing for an IPO, adding to the growing number of quantum computing stocks.",
      "url": "https://finnhub.io/api/news?id=cd873ef285dd87cb3e5f766ef90832f29b6ad2267cb53c25e3f742b7a805e332"
    }
  },
  {
    "ts": null,
    "headline": "XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins?",
    "summary": "Explore why Health Care may mean-revert in 2026. Compare XLV vs BME yields, valuation and NAV discount, plus key risks.",
    "url": "https://finnhub.io/api/news?id=318d9b4b3675a3baea4b15c447112727402dbe4585fb6b8510c5c27f681f97dc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768394359,
      "headline": "XLV Vs. BME: Total Return Or Income, Which Healthcare Strategy Wins?",
      "id": 138113004,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222153/image_2194222153.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Explore why Health Care may mean-revert in 2026. Compare XLV vs BME yields, valuation and NAV discount, plus key risks.",
      "url": "https://finnhub.io/api/news?id=318d9b4b3675a3baea4b15c447112727402dbe4585fb6b8510c5c27f681f97dc"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference",
    "summary": "Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the JPMorgan Healthcare Conference.",
    "url": "https://finnhub.io/api/news?id=d6f8d00d213e88039b110411652e19cc7093e8ec9df7d4de80999607d7c8eb25",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768392531,
      "headline": "Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference",
      "id": 138112555,
      "image": "https://image.cnbcfm.com/api/v1/image/108222573-17624550972025-11-06t184628z_1673660215_rc25rhas1dn5_rtrmadp_0_usa-trump.jpeg?v=1762455130&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Novo Nordisk's CEO spoke about GLP-1 pricing and Pfizer's CEO spoke about the company's obesity ambitions while at the JPMorgan Healthcare Conference.",
      "url": "https://finnhub.io/api/news?id=d6f8d00d213e88039b110411652e19cc7093e8ec9df7d4de80999607d7c8eb25"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (NASDAQ:AMGN) Shares Could Be 49% Below Their Intrinsic Value Estimate",
    "summary": "Key Insights Using the 2 Stage Free Cash Flow to Equity, Amgen fair value estimate is US$637 Current share price of...",
    "url": "https://finnhub.io/api/news?id=3d07f33793184c43348e696a3a43dd47ecff5b0233e72dda1bbf06448cf25612",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768392029,
      "headline": "Amgen Inc. (NASDAQ:AMGN) Shares Could Be 49% Below Their Intrinsic Value Estimate",
      "id": 138111249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Key Insights Using the 2 Stage Free Cash Flow to Equity, Amgen fair value estimate is US$637 Current share price of...",
      "url": "https://finnhub.io/api/news?id=3d07f33793184c43348e696a3a43dd47ecff5b0233e72dda1bbf06448cf25612"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Gold, Silver Hit All-Time Highs As Safe-Haven Demand Surges",
    "summary": "Gold (XAUUSD:CUR) and silver (XAGUSD:CUR) hit fresh all-time highs, with gold up about 1% above $4,641/oz and silver jumping 6% to top $90/oz for the first time.",
    "url": "https://finnhub.io/api/news?id=ea7107a13d97c4883a003e7bb9d6a53f82a6a3eb7f6a940b3c0bce669e547aa2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768390029,
      "headline": "Wall Street Lunch: Gold, Silver Hit All-Time Highs As Safe-Haven Demand Surges",
      "id": 138112348,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/506120376/image_506120376.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Gold (XAUUSD:CUR) and silver (XAGUSD:CUR) hit fresh all-time highs, with gold up about 1% above $4,641/oz and silver jumping 6% to top $90/oz for the first time.",
      "url": "https://finnhub.io/api/news?id=ea7107a13d97c4883a003e7bb9d6a53f82a6a3eb7f6a940b3c0bce669e547aa2"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma",
    "url": "https://finnhub.io/api/news?id=72b1b717a0b8023b92ef414d0e6b32b7c767eef89d6ce78d4a8e2368c22b7281",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768379400,
      "headline": "[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 138109921,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global T-Cell Engagers Market size & share revenue was valued at approximately USD 2.4 Billion in 2024 and is expected to reach USD 2.5 Billion in 2025 and is expected to reach around USD 18.8 Billion by 2034, at a CAGR of 21.2% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Genmab, Roche/Genentech, Ma",
      "url": "https://finnhub.io/api/news?id=72b1b717a0b8023b92ef414d0e6b32b7c767eef89d6ce78d4a8e2368c22b7281"
    }
  }
]